Mesoblast Limited requests trading halt pending financing announcement.
Posted on: 09/01/2025
Mesoblast Limited pauses trading pending further announcement.
AVITA Medical updates 2024 revenue guidance, anticipates significant growth in 2025.
Posted on: 07/01/2025
FDA approves AVITA Medical's RECELL GO mini for smaller wound treatment.
Posted on: 23/12/2024
Patrys Limited receives $1.285 million R&D tax refund.
Posted on: 16/12/2024
Melbourne firm releases significant ASX announcement after trading pause.
Posted on: 05/12/2024
Cambium Bio completes A$3.0 million financing for Phase 3 trials of Elate Ocular.
Posted on: 04/12/2024
FDA grants RMAT designation to Mesoblast's Revascor for congenital heart disease treatment.
Hexima Limited halts acquisition of RealThing Entertainment due to unmet conditions.
Posted on: 03/12/2024
Hexima extends acquisition conditions satisfaction date to December 16, 2024.
Posted on: 26/09/2024
AVITA Medical announces robust Q2 2024 earnings and updates on RECELL product expansion.
Posted on: 08/08/2024
AVITA Medical announces a 29% increase in Q2 revenue and key regulatory approvals.
AVITA Medical announces an 18% revenue increase but reports a 74% rise in net loss.
Cambium Bio announces merger completion and updates on Elate Ocular® Phase 3 trials.
Posted on: 31/07/2024
AVITA Medical secures exclusive rights to a new collagen-based dermal matrix.
Mesoblast provides updates on FDA reviews and financial performance for Q4 2024.
Posted on: 30/07/2024
FDA accepts Mesoblast's BLA for Ryoncil in treating pediatric SR-aGVHD.
Posted on: 23/07/2024
Patrys Limited announces completion of PAT-DX1 production and positive preclinical data for autoimmune diseases.
Posted on: 22/07/2024
Mesoblast resubmits BLA for Ryoncil to treat children with SR-aGVHD.
Posted on: 08/07/2024